A carregar...
Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
INTRODUCTION: Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). There are no approved second line systemic therapies in patients who have had disease progression on or are not eligible to sorafenib. CASE PRESE...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Kowsar
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3830515/ https://ncbi.nlm.nih.gov/pubmed/24282421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5812/hepatmon.11721 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|